ac4

AC-4 is a blocker of photoswitchable TRPV1 channel.

Ac4ManNAz is an azido-containing metabolic glycoprotein labeling reagent. It can be used to selectively modify proteins, and it can be used in cell labeling, tracking and proteomic analysis;

Ac-[Nle4,D-Phe7]-α-MSH (4-10)-NH2, a melanotropin derivative and melanocyte-stimulating hormone, activates tyrosinase and demonstrates a thermoregulatory effect in rat models [1][2].

8-Daucene-2,4,6-triol, O-(4-Hydroxybenzoyl), 2-Ac is a useful organic compound for research related to life sciences and the catalog number is T130945.

AC-4-130, a powerful inhibitor of the SH2 domain of STAT5, effectively hinders STAT5 activation, dimerization, nuclear translocation, and transcription of genes reliant on STAT5. This compound directly binds to STAT5, ultimately leading to cell cycle arrest and apoptosis in FLT3-ITD-driven leukemic cells. AC-4-130 exhibits notable anti-cancer properties and effectively suppresses abnormal STAT5 activity in acute myeloid leukemia (AML), making it a promising therapeutic option [1].

Ac-MBP (4-14) Peptide, an acetylated form of the MBP (4-14) peptide, serves as a highly selective substrate for (protein kinase C) PKC. It facilitates PKC assays in extracts without the need for prior purification to remove interfering protein kinases or phosphatases [1].

H-Phe(4-Ac)-OH, with catalog number T66400 and CAS number 122555-04-8, is a valuable organic compound for life sciences research.

Ac4GalNAlk, a weakly alkyne-labeled reagent for metabolic oligosaccharide engineering (MOE), facilitates the detection of protein glycosylation by promoting nucleotide-sugar biosynthesis and enhancing bioorthogonal cell surface markers. It is activated by cellular biosynthetic machinery into nucleotide sugars, subsequently enabling the tracing of glycoproteins in bioorthogonal chemistry [1].

Ac4GlcNAlk is a alkyl chain-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

HDAC4 CHDI Degrader 11 is a potent, selective degrader of HDAC4 (PROTAC) with DC_50 values of 4 nM and 6 nM in Jurkat E6-1 and Jurkat cells, respectively. This compound integrates the class IIa HDAC inhibitor trifluoromethyloxadiazole with a ligand for the Von Hippel-Lindau (VHL) protein through a linker. Demonstrating significant efficacy, HDAC4 CHDI Degrader 11 achieves a DC_50 value of 1 nM in a mouse cell model of Huntington's disease. For enhanced degradation in neuroblastoma cell lines, it can be administered alongside the P-glycoprotein inhibitor, Elacridar.

AC430 is a potent and specific small molecule inhibitor of janus kinase 2 (JAK2), which has been implicated as a target for therapy in both oncology and autoimmune disease. AC430 is currently being developed by Ambit. In preclinical studies, AC430 has exhibited potency against JAK2 and V617F mutated JAK2 in cell-based models that is at least equivalent to, and in most cases superior to, competing JAK2 inhibitors. In preclinical oncology and autoimmune models, AC430 is well tolerated and has significant efficacy at oral doses as low as 10 mg/kg/day.

Ac4GalNAz is an alkyl chain-based PROTAC linker utilized in PROTAC synthesis.